Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 of  211 نتائج ل ""Proteasome Endopeptidase Complex""

فلترة النتائج

Format : Academic Journals Subject : antineoplastic agents Subject : disease progression Subject : multiple myeloma Subject : terapia celular فلترة بواسطة : موضوع
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.

  • Authors : Zafeiropoulou K; Division of Genetics, Cell Biology and Development, Department of Biology, University of Patras, Patras, Greece.; Hematology Division, Department of Internal Medicine, University of Patras Medical School-University Hospital, Patras, Greece.

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Hematologic Neoplasms*/Hematologic Neoplasms*/Hematologic Neoplasms*/pathology ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy

  • Source: PloS one [PLoS One] 2024 Feb 27; Vol. 19 (2), pp. e0289904. Date of Electronic Publication: 2024 Feb 27 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.

  • Authors : Besse L; Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, 9000, St. Gallen, Switzerland. .; Cantonal Hospital St. Gallen, Rorschacherstrasse 95 Haus 09/218, 9007, St. Gallen, Switzerland. .

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use

  • Source: Scientific reports [Sci Rep] 2023 Mar 17; Vol. 13 (1), pp. 4411. Date of Electronic Publication: 2023 Mar 17.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.

  • Authors : Ambrosio FA; Department of Experimental and Clinical Medicine, Campus 'S. Venuta', University 'Magna Græcia' of Catanzaro, Viale Europa, 88100 Catanzaro, Italy.; Costa G

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/pathology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/adverse effects

  • Source: Molecules (Basel, Switzerland) [Molecules] 2023 Feb 02; Vol. 28 (3). Date of Electronic Publication: 2023 Feb 02.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Entinostat-Bortezomib Hybrids against Multiple Myeloma.

  • Authors : Ferro A; School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/metabolism ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology

  • Source: Molecules (Basel, Switzerland) [Molecules] 2023 Feb 02; Vol. 28 (3). Date of Electronic Publication: 2023 Feb 02.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.

  • Authors : Wang Y; Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.; Gao S

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Bortezomib*/Bortezomib*/Bortezomib*/pharmacology

  • Source: Carcinogenesis [Carcinogenesis] 2022 Dec 25; Vol. 43 (11), pp. 1030-1038.Publisher: Irl Press At Oxford University Press Country of Publication: England NLM ID: 8008055 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells.

  • Authors : Listro R; Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.; Malacrida A

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use; Humans

  • Source: International journal of molecular sciences [Int J Mol Sci] 2022 Oct 27; Vol. 23 (21). Date of Electronic Publication: 2022 Oct 27.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.

  • Authors : Downey-Kopyscinski SL; Department of Molecular and Systems Biology, and Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.; SLDK-Rancho Biosciences, San Diego, CA, USA.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy

  • Source: Scientific reports [Sci Rep] 2022 Jul 27; Vol. 12 (1), pp. 12788. Date of Electronic Publication: 2022 Jul 27.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

Subjects: Biochemistry and Cell Biology; Biological Sciences; Biotechnology

  • Source: Cell Chemical Biology. 29(8)

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance.

  • Authors : Leonardo-Sousa C; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.; Carvalho AN

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy

  • Source: Molecules (Basel, Switzerland) [Molecules] 2022 Mar 28; Vol. 27 (7). Date of Electronic Publication: 2022 Mar 28.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.

  • Authors : Besse A; Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland.; Kraus M

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology ; Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy

  • Source: Cells [Cells] 2022 Mar 01; Vol. 11 (5). Date of Electronic Publication: 2022 Mar 01.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 of  211 نتائج ل ""Proteasome Endopeptidase Complex""